OAC resumption does not increase the risk of recurrent ICH and can also reduce the risk of all-cause mortality. OAC cessation exposes patients to a significantly higher risk of thromboembolism, which could be reduced by resumption. The optimal timing of anticoagulation resumption after ICH is still unknown. Both early (< 2 weeks) and late (> 4 weeks) resumption should be reached only after very careful assessment of risks for ICH recurrence and thromboembolism. The introduction of new oral anticoagulants and other interventions, such as left atrial appendage closure, has provided some patients with more alternatives. Given the lack of high-quality evidence to guide clinical decision-making, clinicians must carefully balance the risks of thromboembolism and recurrent ICH in individual patients. We propose a management approach which would facilitate the decision-making process on whether anticoagulation is appropriate, as well as when and how to restart anticoagulation after ICH.
José Miguel Rivera‐Caravaca, María Asunción Esteve‐Pastor, Anny Camelo‐Castillo, Inmaculada Ramírez-Macías, Professor Gregory Lip, Vanessa Roldán, Francisco Marı́n
Truman J. Milling, Steven Warach, S. Claiborne Johnston, Byron Gajewski, Todd W. Costantini, Michelle A. Price, Jo Wick, Simin Roward, Dinesh Pal Mudaranthakam, Adrienne N. Dula, Ben King, Alexander Muddiman, Professor Gregory Lip
Discussion(0)
No comments yet. Be the first to comment.